It is made available under a CC-BY-ND 4.0 International license perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.10.18.22281202;](https://doi.org/10.1101/2022.10.18.22281202) this version posted October 20, 2022. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

Abstract

- Hospital admission for COVID-19 remains common despite the successful development of vaccines
- and treatments. Thus, there is an ongoing need to identify targets for new COVID-19 therapies.
- Alternative splicing is an essential mechanism for generating functional diversity in protein isoforms
- 37 and influences immune response to infection. However, the causal role of alternative splicing in
- COVID-19 severity and its potential therapeutic relevance is not fully understood. In this study, we
- evaluated the causal role of alternative splicing in COVID-19 severity and susceptibility using
- Mendelian randomization (MR). To do so, we performed two-sample MR to assess whether *cis*-sQTLs
- spanning 8,172 gene splicing in 5,295 genes were associated with COVID-19 outcomes in the
- COVID-19 Host Genetics Initiative, including up to 158,840 COVID-19 cases and 2,782,977
- population controls. We identified that alternative splicing in lungs, rather than total RNA expression of
- *OAS1*, *ATP11A*, *DPP9* and *NPNT*, was associated with COVID-19 severity. *MUC1* splicing was
- associated with COVID-19 susceptibility. Further colocalization analyses supported a shared genetic
- mechanism between COVID-19 severity with idiopathic pulmonary fibrosis at *ATP11A* and *DPP9* loci,
- and with chronic obstructive lung diseases at *NPNT*. We lastly showed that *ATP11A, DPP9, NPNT*,
- and *MUC1* were highly expressed in lung alveolar epithelial cells, both in COVID-19 uninfected and
- infected samples. Taken together, these findings clarify the importance of alternative splicing of
- proteins in the lung for COVID-19 and other respiratory diseases, providing isoform-based targets for
- drug discovery.
-

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) . perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.10.18.22281202;](https://doi.org/10.1101/2022.10.18.22281202) this version posted October 20, 2022. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

Introduction

Results

MR using cis-sQTLs, and colocalization analyses

 The study design is illustrated in **Fig. 1**. We obtained the genetic determinants of gene splicing (splicing quantitative trait locus [sQTL]) that influence alternative splicing events, which were quantified as normalized intron excision ratios, *i.e.* the proportion of reads supporting each 97 alternatively excised intron, by LeafCutter²⁰ (using a multiple-testing correction threshold of a false 98 discovery rate of 5% per tissue) in GTEx v.8¹⁹. We chose to examine only *cis-sQTLs*, which act *cis* to the coding genes, as it is less likely that these act through horizontal pleiotropy, where the SNPs have effects on diseases (here, COVID-19 outcomes) independently of the gene splicing. We also focused on two COVID-19-relevant tissues; lungs (N=515, of which 452 were of European American ancestry) and whole blood (N=670, of which 570 were of European American ancestry) since pulmonary symptoms are the major determinant of hospital admission and the immune system plays a major role 104 in host response to SARS-CoV-2.

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) . perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.10.18.22281202;](https://doi.org/10.1101/2022.10.18.22281202) this version posted October 20, 2022. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

131 p46 isoform, a prenylated form of OAS1 with higher anti-viral activity than the p42 isoform^{22–24} (**Fig. 2,**

Extended Data Fig. 1A, Supplementary Table 1,2).

We additionally identified that *ATP11A* sQTL, rs12585036:T>C, which increases the excision of the

intron junction at chr13:112,875,941-112,880,546 in lung, was associated with protection against all

136 three adverse COVID-19 outcomes with odds ratio [OR] per normalized intron excision ratio [the

137 proportion of reads supporting each alternatively excised intron identified by LeafCutter²⁰] of 0.78

138 (95%CI: 0.73-0.82, p=9.3x10⁻¹⁹) for critical illness, OR of 0.84 (95%CI: 0.81-0.87, p=3.1x10⁻²¹) for

hospitalization, and OR of 0.96 (0.94-0.97, p=2.9x10-6) for reported infection (**Fig. 2, Extended Data**

Fig. 1B, Supplementary Table 1).

We also found novel associations of *DPP9* sQTL, rs12610495:G>A, which increases the excision of

the intron junction at chr19:4,714,337-4,717,615 in lung, with protection against all three adverse

144 COVID-19 outcomes (OR: 0.49, 0.45-0.54, p=5.5x10⁻⁵⁹ for critical illness, OR: 0.64, 0.61-0.68,

p=4.0x10⁻⁵² for hospitalization, and OR: 0.85, 0.83-0.88, p=3.2x10⁻²⁹ for reported infection, **Fig. 2**).

DPP9 has two major isoforms, DPP9L (longer isoform, 863 aa, ENST00000262960) and DPP9S

147 (shorter isoform, 863 aa, ENST00000598800)²⁵, and they differ in the presence of the skipping of exon

9 (chr19:4,715,529-4,716,152), which overlaps the intron junction at chr19:4,714,337-4,717,615

(**Extended Data Fig. 1C, Supplementary Table 1**).

NPNT rs34712979:A>G, which increases the intron junction of chr4:105,898,001-105,927,336

(**Extended Data Fig. 1D**), was associated with increased risk of severe COVID-19 outcomes (critical

illness and hospitalization) but with marginal evidence of increased risk of SARS-CoV-2 infection (OR:

154 1.18, 1.12-1.24, p=5.5x10⁻¹⁰ for critical illness, OR: 1.10, 1.07-1.14, p=3.8x10⁻⁸ for hospitalization, and

OR: 1.02, 1.00-1.03, p=4.2x10-2 for reported infection, **Fig. 2, Supplementary Table 1**). The *NPNT*

- sQTL, rs34712979-A allele, creates a NAGNAG splice acceptor site, which results in additional in-
- 157 frame AGT codon, coding for serine, at the 5' splice site of exon 2^{26} .
-
- Gene splicing in the two genes in the gene cluster located in chr1 q21.3-q22, namely *MUC1* and
- *THBS3*, in lung were also associated with reported SARS-CoV-2 infection, but not with COVID-19
- severity phenotypes (**Fig. 2**, **Supplementary Table 1**). Given that the *MUC1* and *THBS3* sQTL SNPs
- are in high LD with each other (rs4072037:C>T and rs2066981:A>G; r2=0.98 in European population
- of 1000G), it was challenging to distinguish which genes were more likely to be causal between *MUC1*
- and *THBS3*. Nevertheless, *MUC1* sQTL SNP, rs4072037:C>T, is a recognized splice variant which
- 165 influences the 3' splice site selection of exon2 27 . In GTEx, the rs4072037-T allele was associated with
- decreased levels of the intron junction of chr1:155,192,310:155,192,786 (**Extended Data Fig. 1E**),
- 167 which leads to transcripts that have an alternative 27 bp intron retention event at the start of exon 2^{27} .
- We demonstrated the rs4072037-C allele, which increases the levels of the intron junction of
- chr1:155,192,310:155,192,786, was associated with increased risk of reported SARS-CoV-2 infection.
- Given the well-known evidence of the splicing event of *MUC1*, it is more likely that *MUC1* gene
- splicing has an impact of SARS-CoV-2 infection.
-
- All of the above associations of gene splicing, except for *MUC1,* were more pronounced with more
- severe outcomes (**Fig. 2**). We also applied MR for another hospitalization phenotype compared within
- COVID-19 cases ("hospitalization vs non-hospitalization amongst individuals with laboratory-confirmed
- 176 SARS-CoV-2 infection", which corresponds to B1 phenotype in COVID-19 HGI¹¹). We confirmed the
- 177 associations with gene splicing in *ATP11A* and *DPP9* (*ATP11A*: OR 0.87, 0.81-0.94, p=4.6x10⁻⁴, and
- *DPP9*: OR 0.83, 0.73-0.94, p=4.9x10-3) but not with gene splicing in *NPNT* and *OAS1*
- (**Supplementary Table 3**).
-
-

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) . perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.10.18.22281202;](https://doi.org/10.1101/2022.10.18.22281202) this version posted October 20, 2022. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

Colocalization and European-only MR analyses

hospitalization, but had as low PP as 0.02 for reported infection (**Fig. 3C**). All of these gene splicing

207 had a support from European-descent only MR analysis with similar effect estimates as the main

208 analyses (p<5.1x10⁻⁶, **Supplementary Table 4,5**).

Colocalization with eQTL GWASs from GTEx

Next, to understand if total gene expression levels in lung and whole blood were associated with

COVID-19 outcomes, without respect to the splicing or isoforms, we performed MR and colocalization

analyses using expression quantitative trait loci (eQTLs) in lung and whole blood from GTEx. The total

215 expression of *GBAP1* had MR evidence with reported SARS-CoV-2 infection (p=5.9x10⁻⁸) and the

eQTLs of *ABO, GBAP1,* and *MOSPD3*, had high colocalization with COVID-19 outcomes (PP >0.8,

Supplementary Table 6,7). Thus, for those genes, we could not clarify whether the associations with

COVID-19 outcomes were driven by either total gene expression or the spliced isoform expression or

both.

Influence of prioritized sQTLs on other diseases.

223 We next searched for the effects of the sQTLs, which influence COVID-19 outcomes, on other 224 diseases. To do so, we used the Open Targets Genetics^{30,31} (https://genetics.opentargets.org) and 225 identified GWAS lead variants that were in LD (r^2 >0.80) with COVID-19 associated sQTLs. We found that the *DPP9* sQTL (rs12610495:G>A) was associated with decreased risk of idiopathic pulmonary 227 fibrosis (IPF) and the same allele confers the protection against COVID-19 severity. Interestingly, we found the opposite direction of effects between IPF and COVID-19 in the sQTL for *ATP11A*, where the rs12585036-C allele was associated with increasing risk of IPF and decreased risk for COVID-19

 severity. The *NPNT* sQTL had similar trend that rs34712979-A allele, which was protective for COVID- 19 severity, was associated with increased risk of COPD (*i.e.* lower FEV1/FVC ratio, a spirometry 232 measurement used to diagnose COPD)^{33,34} and with increased risk of asthma³⁵. The OAS1 sQTL (rs10774671:A>G) was associated with a decreased risk of systemic lupus erythematosus (in the East 234 Asian population)³⁶ and with an increased risk of chronic lymphocytic leukemia³⁷. The MUC1 sQTL (rs4072037:T>C) was associated with decreased risk of gastric cancer³⁸, gout³⁹, and inflammatory bowel disease⁴⁰.

238 We then performed colocalization analyses in each sQTL locus between COVID-19 outcomes and the 239 other associated diseases/phenotypes if the effects were supported in European population and there was genome-wide GWAS summary data available. IPF 32 and critical illness due to COVID-19 were highly colocalized at the *ATP11A* and *DPP9* sQTL loci with PP of 1.00. The FEV1/FVC ratio also 242 colocalized with critical illness due to COVID-19 with a PP of 1.00. Inflammatory bowel disease⁴⁰ and urate level (which is the cause of gout) also colocalized with reported SARS-CoV-2 infections at the *MUC1* locus (both PPs are 1). We found no GWAS summary statistics available for the other diseases (**Table 1**). These lines of evidence suggest that IPF and COVID-19 severity, COPD/asthma and 246 COVID-19 severity, and IBD and COVID-19 susceptibility may share causal genetic determinants in these loci, respectively. The full results and the data used are summarized in **Table 1**.

The tissue and cell-type specific expression of the associated genes

 To assess the relevant tissues and cell-types for the associated gene splicing – COVID-19 outcome relationships, we evaluated the associated gene expression in lung and peripheral blood mononuclear 253 cell (PBMC) of healthy controls, as well as in lung of COVID-19 patients. In the consensus transcript expression levels from Human Protein Atlas (HPA)41 and GTEx, the expression of *ATP11A*, and *NPNT* were highly enriched in normal lung tissue (**Fig. 4A**). At a single-cell resolution, in normal lung, *MUC1*,

- *ATP11A* and *NPNT* were specifically enriched in alveolar type 1 and 2 epithelial cells (**Fig. 4B**), which
- 257 are known to play important roles in regeneration of alveolar epithelium following lung injury⁴². In 23
- lung COVID-19 autopsy donor tissue samples from GSE17166843 , the expression of *ATP11A, DPP9,*
- *MUC1,* and *NPNT* were also enriched in alveolar type 1 and 2 epithelial cells (**Fig. 4C**). Taken
- together, these expression evidence suggests that the gene splicing COVID-19 outcome
- relationships for *ATP11A, DPP9, MUC1,* and *NPNT* were highly likely to be relevant in lung tissue,
- especially alveolar epithelial cells for *ATP11A*, *MUC1*, and *NPNT*.
-
-

Discussion

- Despite current vaccines and therapeutic options, hospitalization for COVID-19 remains high in many
- countries. Thus, there remains a need for additional therapies, which in turn, requires target
- identification and validation⁴⁴. In this large-scale two-sample MR study of 8,172 gene splicing events
- assessed for their effect upon three COVID-19 outcomes in up to 158,840 COVID-19 cases and
- 2,782,977 population controls, we provide evidence that alternative splicing of *OAS1, ATP11A*, *DPP9*
- and *NPNT* in lung influences COVID-19 severity, and alternative splicing of *MUC1* in lung influences
- COVID-19 susceptibility. Moreover, these genetic mechanisms are likely shared with other diseases,
- such as *ATP11A* and *DPP9* with IPF, suggesting the potential to be targeted for multiple diseases.
- 274 Our results provide rationale to target gene splicing in lung as COVID-19 treatment by means of
- 275 therapeutic modalities such as splice-switching oligonucleotides (SSOs).
-

 SSOs are a type of antisense oligonucleotides which are generally 15–30 nucleotides in length and are designed as complementary to specific regions of mRNA with increased stability against 279 endogenous nucleases due to chemical modifications⁴⁵. SSOs can prevent splicing promoting factors from binding to the target pre-mRNA, which can modulate alternative splicing⁴⁶. Some SSOs have 281 been already approved by FDA, such as eteplirsen for Duchenne's muscular dystrophy, which induces

282 the skipping of exon 51 of *DMD* gene, and nusinersen for spinal muscle atrophy, which induces the 283 expression of exon 7 of *SMN2* gene⁴⁵. Although delivery to target tissues after systemic administration 284 has been a key challenge in the development of SSO drugs $45,47$, lung might be advantageous tissue to 285 target since it is possible to deliver drugs directly to lung through inhalation and/or bronchoscopy. 286 287 There are multiple sources of biological evidence which might support the relevance of *ATP11A* in 288 COVID-19. *ATP11A* is a member of the P4-ATPase family, which codes for a phospholipid flippase at 289 the plasma membrane and translocates phosphatidylserine (PtdSer) from the outer to the inner leaflet 290 of plasma membranes. Cells that undergo apoptosis, necroptosis or pyroptosis expose PtdSer on their 291 surface through P4-ATPase, of which *ATP11A* is cleaved by caspase during apoptosis⁴⁸. While less 292 functionally defined, given the high expression of *ATP11A* in the alveolar type 2 epithelial cells*,* 293 *ATP11A* sQTL (rs12585036:C>T) may impact the cell death of alveolar type 2 epithelial cells, the 294 resident stem cell population in lung⁴⁹, and may impair regeneration of alveolar epithelium following 295 lung injury. 296 297 Our MR analysis showed that the excision of intron junction chr19:4,814,337-4,717,615, which may be 298 preferentially spliced in DPP9L than in DPP9S, was associated with reduced risk of COVID-19 299 severity. While both DPP9L and DPP9S can be active²⁵, DPP9S is present in the cytosol, and DPP9L 300 localizes preferentially to the nucleus, which may be attributed to a classical monopartite nuclear δ 101 localization signal (RKVKKLRL) in the N-terminal extension of DPP9L²⁵. Although it is not fully 302 understood how the *DPP9* sQTL (rs12610495:A>G) regulates alternative splicing of *DPP9*, 303 rs12610495-G allele creates a GGGG motif (from GGAG sequence), which may have an effect on 304 alternative splicing of some genes⁵⁰. DPP9 interacts with NLRP1 and represses inflammasome 305 activation⁵¹ and pyroptosis, which are now recognized as important mechanisms interrupting the viral 306 replication cycle and preventing viral amplification of SARS-CoV- 2^{52} . Moreover, targeting

 inflammasome-mediated hyperinflammation in COVID-19 patients may also prevent chronic phase of COVID-19 pathophysiology in vivo⁵².

 Our MR analyses supported that the *MUC1* gene splicing associated with susceptibility of SARS-CoV- 2 infection. *MUC1* is a mucin, which is also called KL-6 in human, and the serum level of KL-6 is used as a biomarker for interstitial lung diseases⁵³. rs4072037-T allele was associated with the decreased level of the intron junction of chr1:155,192,310:155,192,786, which corresponds to transcripts with an alternative 27 bp intron retention event at the start of exon 227 . *MUC1* exon 2 harbors a variable number of tandem repeats (VNTR) that contains 20 to 125 repeats of a 60 bp coding sequence that 316 determines the length of a heavily glycosylated extracellular domain⁵⁴. Although rs4072037 may or may not control the alternative splicing of VNTR region³⁸, in addition to the alternative 27 bp intron 318 retention²⁷, the VNTR length of *MUC1* is associated with several renal phenotypes in recent study in 319 UK Biobank⁵⁵. The rs4072037-T allele has been shown to be associated with increased risk of gastric 320 cancer in both European and East Asian ancestries^{38,56} and it is hypothesized that the MUC1 gene is involved in response to *H.pylori* colonization in gastric epithelial surfaces. Taken together, it is plausible that alternative splicing of *MUC1* in lung alveolar cells has an impact on SARS-CoV-2 infection. This study has limitations. First, the excised intron junction was quantified in an annotation-free manner using LeafCutter²⁰, without respect to the level of transcripts nor isoforms. It is thus important 327 for future work to map those disease-relevant alternative splicing events to the corresponding isoform or protein product, by means of emerging technologies such as long-read sequencing⁵⁷ and high-

329 throughput protein quantification⁵⁸. We anticipate our findings, and others, will motivate the ongoing

effort to do so. Second, we used MR to test the effect of gene splicing measured in a non-infected

state since the effect of the *cis-*sQTLs upon gene splicing was estimated in individuals who had not

332 been exposed to SARS-CoV-2. Given the dynamic gene regulation of splicing during infection⁵⁹, gene

 splicing could be altered once a person experiences SARS-CoV-2 infection. Thus, the MR results presented in this paper should be interpreted as an estimation of the effect of gene splicing during uninfected state. Future studies may help to clarify if the same *cis-*sQTLs regulate alternative splicing during infection. Third, it was not our goal to identify all alternative splicing that affects COVID-19 337 outcomes, but rather to provide strong evidence for a small set of genes with strong MR and colocalization evidence. Thus, we acknowledge a high false-negative rate of our study design. Although we attempted to include the data from individuals of diverse ancestries, most individuals were of European descent. Therefore, we could not confirm that our findings could be robustly transferrable to individuals of other populations. Fourth, while our findings demonstrate that effects of alternative splicing in lung and whole blood since these are relevant to COVID-19 severity, we 343 recognize that these splicing events may not be unique to these tissues and thus the estimated effects of splicing may represent the action of these same alternative transcripts in other tissues. Lastly, a 345 recent paper⁶⁰ reported that the shared genetic signal between IPF and COVID-19 outcomes at the *DPP9* and *ATP11A* loci are likely driven by the difference of total expression in whole blood, which 347 was supported by colocalization using eQTLGen⁶¹ dataset. However, eQTLGen consists of multi- ancestry cohorts and could be affected by the bias due to LD. Moreover, we demonstrated that both *DPP9* and *ATP11A* expression were enriched in alveolar cells in lung, compared to whole blood. Thus, we concluded that it is more likely that the alternative splicing of *DPP9* and *ATP11A* in lung is important both for IPF and COVID-19 severity.

 In conclusion, we have used genetic determinants of gene splicing and COVID-19 outcomes obtained from large-scale studies and found compelling evidence that splicing events in *OAS1, ATP11A, DPP9, NPNT*, and *MUC1* have causal effects on COVID-19 severity and susceptibility. Interestingly, the available evidence suggests shared genetic mechanisms for COVID-19 severity with IPF at *ATP11A* and *DPP9* loci, and with chronic obstructive lung diseases at the *NPNT* locus. Taken together, our

- study highlights the importance of alternative splicing both in COVID-19 and other diseases, which
- could be further investigated for drug discovery such as SSOs.
-
-
- **Methods**
- *Splicing quantitative trait loci (sQTL) GWASs*
- We obtained all conditionally independent splicing quantitative trait loci (sQTLs) in lung (N=515, of which
- 452 were of European ancestry) and whole blood (N=670, of which 570 were of European ancestry) that
- act in *cis* (in a +/- 1Mb window around the transcription start site of each gene with normalized intron
- 367 excision ratios from LeafCutter²⁰ (5% FDR per tissue). Conditional independent sQTLs were mapped
- using stepwise regression in GTEx consortium¹⁹. Intron excision ratios are the proportion of reads
- supporting each alternatively excised intron identified by LeafCutter²⁰. We selected lung and whole blood
- since they are the two major tissues relevant to COVID-19 pathophysiology.
-
-

COVID-19 GWASs

- To assess the association of *cis-*sQTLs with COVID-19 outcomes, we used COVID-19 GWAS meta-
- analyses results from the COVID-19 Host Genetics Initiative (HGI) release 7^{11}
- (https://www.covid19hg.org/results/r7/). The outcomes tested were critical illness, hospitalization, and
- reported SARS-CoV-2 infection (named A2, B2, and C2, respectively by the COVID-19 HGI).
-
- Critically ill COVID-19 cases were defined as those individuals who were hospitalized with laboratory-
- confirmed SARS-CoV-2 infection and who required respiratory support (invasive ventilation, continuous
- positive airway pressure, Bilevel Positive Airway Pressure, or continuous external negative pressure,
- high-flow nasal or face-mask oxygen) or who died due to the disease. Simple supplementary oxygen
- (e.g. 2 liters/minute via nasal cannula) did not qualify for case status. Hospitalized COVID-19 cases were

- In a sensitivity analysis, we also used another hospitalization phenotype (named B1 in the COVID-19
- HGI), where cases were hospitalized COVID-19 cases and controls were defined as non-hospitalized

individuals with laboratory-confirmed SARS-CoV-2 infection.

Two-sample Mendelian randomization

 We used two-sample mendelian randomization (MR) analyses using "TwoSampleMR v0.5.6" R 399 package⁶² to screen and test the potential role of alternative splicing in lung and whole blood to influence COVID-19 outcomes. In two-sample MR, the effect of SNPs on the exposure and outcome are taken from separate GWASs. Two-sample MR often improves statistical power and is less biased than one- sample MR, with potential bias in the direction to the null⁶³. MR is less affected by confounding and reverse causality than observational epidemiology studies. The MR framework is based on three main assumptions: First, the SNPs are robustly associated with the exposure (*i.e*. a lack of weak instrument bias). We validated that all *cis*-sQTLs had a F-statistic >10, corresponding to T-statistics >3.16, which indicate a low risk of weak instrument bias in MR analyses⁶⁴. Second, the SNPs are not associated with any confounding factors for the relationship between the exposure and the outcome. Third, the SNPs have no effect on the outcome that is independent of the exposure (*i.e.* a lack of horizontal pleiotropy), which is the most challenging assumption to assess. Nevertheless, in order to reduce the risk of

 horizontal pleiotropy, we selected *cis-*sQTLs as instrumental variables, as *cis-*SNPs that reside close to 411 the genes are more likely to have an effect on the outcomes by directly influencing the splicing of the gene. Palindromic *cis*-sQTLs with minor allele frequencies (MAF) >0.42 were removed prior to MR to prevent allele-mismatches. For gene splicing with a single (sentinel) *cis-*sQTL, we used the Wald ratio to estimate the effect of each splicing event on each of the three COVID-19 outcomes. For any gene splicing event with multiple conditionally independent *cis*-sQTLs, an inverse variance weighted (IVW) method was used to meta-analyze their combined effects. After harmonizing the *cis-*sQTLs with COVID- 19 GWASs, a total of 5,999 splicing events in 4,477 genes (6,110 matched *cis-*sQTLs) in lung and a total of 3,769 splicing events in 2,779 genes (3,883 matched *cis-*sQTLs) in whole blood were used for the MR 419 analyses across the three COVID-19 outcomes. We applied the Bonferroni corrected p-value (5.1x10⁻⁶) to adjust for multiple testing, by using the number of splicing events tested (5,999 in lung and 3,769 in whole blood, in total 8,172).

European-only MR analyses and colocalization analysis

 Next, we assessed potential confounding by population stratification and linkage disequilibrium (LD). To do so, we first repeated MR analyses using the data from individuals of European ancestry. We obtained the effect estimate of each *cis-*sQTL from the data mapped in European-American subjects. If the *cis-*

sQTL was missing in the summary data mapped in European-ancestry subjects, we removed those *cis-*

429 sQTLs in the analyses. The three COVID-19 outcomes GWASs results were also replaced by the meta-

analyses summary results of European-ancestry subjects.

We also evaluated whether the gene splicing and COVID-19 outcomes shared a common etiological

genetic signal and that the MR results were not biased by linkage disequilibrium (LD) using colocalization

analyses with the data from individuals of European ancestry. Specifically, for each of these MR

significant splicing events, a stringent Bayesian analysis was implemented in "coloc v 5.1.0.1" R package

- to analyze all variants in 1MB genomic locus centered on the *cis*-sQTL. Colocalizations with posterior
- 437 probability for high colocalization (PP > 0.8), that is, that there is an association for both gene splicing and
- COVID-19 outcomes, and they are driven by the same causal variant were considered to colocalize,
- which means that the exposure and the outcome shared a single causal variant.
-
-
- *Mendelian randomization and Colocalization with eQTL GWASs from GTEx*
- 443 To understand if the total gene expression levels in lung and whole blood were associated with
- COVID-19 outcomes, without respect to the splicing or isoforms, we similarly performed MR and
- colocalization analyses using expression quantitative trait loci (eQTLs) in lung and whole blood from
- 446 GTEx v.8¹⁹ (lung: N=515, of which 452 were of European ancestry, and whole blood: N=670, of which
- 570 were of European ancestry) by restricting the regions within 1 Mb of each QTL. The genetic
- 448 instruments were conditionally independent eQTLs for the prioritized sQTL genes in lung and/or whole
- blood, all of which had strong support for colocalization between sQTLs and COVID-19 outcomes.
-

Influence of identified sQTLs on other diseases

- We assessed the effects of the sQTLs which influence COVID-19 outcomes on other diseases.
- 453 Pleiotropic search was performed using Open Targets Genetics^{30,31} (https://genetics.opentargets.org)
- 454 and identified any GWAS lead variants that are in LD (r^2 >0.80) with those sQTLs. Colocalization
- analyses were performed using "coloc v 5.1.0.1" R package when there is available GWAS summary
- 456 statistics of European ancestry.
-
- *The tissue and cell-type specific expression of the associated genes*
- To assess the relevant tissues and cell-types for the associated gene splicing COVID-19 outcome
- relationships, we evaluated the associated gene expression in lung and peripheral blood mononuclear
- cell (PBMC) of healthy controls, as well as in lung of COVID-19 patients. We first downloaded

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) . perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.10.18.22281202;](https://doi.org/10.1101/2022.10.18.22281202) this version posted October 20, 2022. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

487 sQTLMR for review and reuse.

488 **Table 1. Colocalization analyses of COVID-19 outcomes and other diseases at the identified sQTL loci.**

489 EA: effect allele, NEA: non-effect allele, PP: a posterior probability that there is an association for both gene expression/splicing and COVID-19 outcomes,

490 which is driven by the same causal variant. PP was only estimated when there is an available GWAS summary statistics of European ancestry.

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.10.18.22281202;](https://doi.org/10.1101/2022.10.18.22281202) this version posted October 20, 2022. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

491 **Fig. 1. Flow Diagram of Study Design**

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.10.18.22281202;](https://doi.org/10.1101/2022.10.18.22281202) this version posted October 20, 2022. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

517 **Fig. 2. MR estimates of the effect of gene splicing at** *ATP11A, DPP9, NPNT, OAS1***, and** *MUC1*

518 **with COVID-19 outcomes**

519 Forest plot showing odds ratio and 95% confidence interval from two sample Mendelian

520 Randomization analyses (two-sided). P values are unadjusted. Unit: standard deviation of intron

521 excision ratios as quantified by LeafCutter.

522 **Fig. 3. LocusZoom plots demonstrating the colocalization of the genetic determinants of mRNA** 523 **expression, gene splicing levels and COVID-19 outcomes** LocusZoom plots of genetic signal of 524 1MB region around each *cis*-sQTL and COVID-19 outcomes, color shows SNPs in the region in LD (r2 525) to the *cis*-sQTL. (A) *ATP11A* (B) *DPP9* (C) *NPNT* (D) *MUC1*

532 **Figure 4. The gene expression in lung and peripheral blood mononuclear cell (PBMC).**

- 533 A. The consensus transcript expression levels summarized per gene in 54 tissues in Human Protein Atlas (HPA), which was calculated as the maximum
- 534 transcripts per million value (TPM) value for each gene in all sub-tissues categories of each tissue, based on transcriptomics data from HPA and
- 535 GTEx.
- 536 B. RNA single cell type tissue cluster data (transcript expression levels summarized per gene and cluster) of lung (GSE130148) and peripheral blood
- 537 mononuclear cell (PBMC) (GSE112845) were visualized using log₁₀(protein-transcripts per million [pTPM]) values. Each c-X annotation is taken from
- 538 the clustering results performed in Human Protein Atlas.
- 539 C. Single-cell RNA expression profile of 23 lung COVID-19 autopsy donor tissue samples from GSE171668⁴³. The mean value of RNA expression of the
- 540 cells annotated in the same subcategory was represented as a dot per each sample. The cell type annotation was manually performed in the original
- 541 publication⁴³. AT1: alveolar type 1 epithelial cells, AT2: alveolar type 2 epithelial cells, EC: endothelial cells, *KRT8*⁺ PATS/ADI/DATPs: *KRT8*⁺ pre-
- 542 alveolar type 1 transitional cell state, MAST: mast cells, XXhi: XX (gene expression) *high* cells, RBC: red blood cells.
- 543 **Extended Data Fig. 1. LocusZoom plots demonstrating the colocalization of the genetic**
- 544 **determinants of mRNA expression, gene splicing levels for** *OAS1* **and COVID-19 outcomes.**
- 545 LocusZoom plots of genetic signal of 1MB region around each *cis*-sQTL and COVID-19 outcomes,
- 546 color shows SNPs in the region in LD (r^2) to the *cis*-sQTL for *OAS1*.
-

548 **Extended Data Fig. 2. The gene plots.**

549 The major gene-coding transcripts were manually curated to visualize, in relation to the sQTLs and the excised introns quantified by LeafCutter.

550 (A) *OAS1* (B) *ATP11A* (C) *DPP9* (D) *NPNT* (E) *MUC1*

551

Contributions

- (365825; 409511, 100558, 169303), the Lady Davis Institute of the Jewish General Hospital, the
- Canada Foundation for Innovation (CFI), the NIH Foundation, Cancer Research UK, Genome
- Québec, the Public Health Agency of Canada, the McGill Interdisciplinary Initiative in Infection and
- Immunity and the Fonds de Recherche Québec Santé (FRQS). TN is supported by a research
- fellowship of the Japan Society for the Promotion of Science for Young Scientists. Support from Calcul
- Québec and Compute Canada is acknowledged.
-
-

References

- 1. Haas, E. J. *et al.* Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-
- CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a
- nationwide vaccination campaign in Israel: an observational study using national
- surveillance data. *The Lancet* **397**, 1819–1829 (2021).
- 2. Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N.*
- *Engl. J. Med.* **383**, 2603–2615 (2020).
- 3. Dexamethasone in Hospitalized Patients with Covid-19 Preliminary Report. *N. Engl. J.*
- *Med.* 1–11 (2020) doi:10.1056/nejmoa2021436.
- 4. Hammond, J. *et al.* Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-
- 19. *N. Engl. J. Med.* **386**, 1397–1408 (2022).
- 5. Huang, L. *et al.* 1-year outcomes in hospital survivors with COVID-19: a longitudinal
- cohort study. *The Lancet* **398**, 747–758 (2021).
- 6. The Lancet. Understanding long COVID: a modern medical challenge. *The Lancet* **398**,
- 725 (2021).
- 7. Piroth, L. *et al.* Comparison of the characteristics, morbidity, and mortality of COVID-19
- and seasonal influenza: a nationwide, population-based retrospective cohort study. *Lancet*
- *Respir. Med.* **9**, 251–259 (2021).
- 8. Iacobucci, G. Covid and flu: what do the numbers tell us about morbidity and deaths?
- *BMJ* **375**, n2514 (2021).

- indications. *Nat. Genet.* **47**, 856–860 (2015).
- 16. Cook, D. *et al.* Lessons learned from the fate of AstraZeneca's drug pipeline: a five-
- dimensional framework. *Nat. Rev. Drug Discov.* **13**, 419–31 (2014).
- 17. Kornblihtt, A. R. *et al.* Alternative splicing: a pivotal step between eukaryotic
- transcription and translation. *Nat. Rev. Mol. Cell Biol. 2013 143* **14**, 153–165 (2013).
- 18. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host
- genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. *Eur. J.*
- *Hum. Genet.* **28**, 715–718 (2020).
- 19. Aguet, F. *et al.* The GTEx Consortium atlas of genetic regulatory effects across human
- tissues. *Science* (2020) doi:10.1126/SCIENCE.AAZ1776.
- 20. Li, Y. I. *et al.* Annotation-free quantification of RNA splicing using LeafCutter. *Nat.*
- *Genet.* (2018) doi:10.1038/s41588-017-0004-9.
- 21. Ben-Eghan, C. *et al.* Don't ignore genetic data from minority populations Setting the
- agenda in research. *ALAMY 184 Nat.* **585**, (2020).
- 22. Zhou, S. *et al.* A Neanderthal OAS1 isoform protects individuals of European ancestry
- against COVID-19 susceptibility and severity. *Nat. Med.* 1–9 (2021) doi:10.1038/s41591-
- 021-01281-1.
- 23. Huffman, J. E. *et al.* Multi-ancestry fine mapping implicates OAS1 splicing in risk of
- severe COVID-19. *Nat. Genet. 2022* 1–3 (2022) doi:10.1038/s41588-021-00996-8.
- 24. Wickenhagen, A. *et al.* A prenylated dsRNA sensor protects against severe COVID-19.
- *Science* **374**, (2021).

- 50. Královic̆ová, J. & Vor̆echovský, I. Position-Dependent Repression and Promotion of
- *DQB1* Intron 3 Splicing by GGGG Motifs. *J. Immunol.* **176**, 2381–2388 (2006).
- 51. Hollingsworth, L. R. *et al.* DPP9 sequesters the C terminus of NLRP1 to repress
- inflammasome activation. *Nature* **592**, 778–783 (2021).
- 52. Sefik, E. *et al.* Inflammasome activation in infected macrophages drives COVID-19
- pathology. *Nature* **606**, 585–593 (2022).

123, 3025–3036 (2013).

- 53. Ishikawa, N., Hattori, N., Yokoyama, A. & Kohno, N. Utility of KL-6/MUC1 in the
- clinical management of interstitial lung diseases. *Respir. Investig.* **50**, 3–13 (2012).
- 54. Fowler, J. C., Teixeira, A. S., Vinall, L. E. & Swallow, D. M. Hypervariability of the
- membrane-associated mucin and cancer marker MUC1. *Hum. Genet.* **113**, 473–479
- (2003).
- 55. Mukamel, R. E. *et al.* Protein-coding repeat polymorphisms strongly shape diverse human
- phenotypes. *Science* **373**, 1499–1505 (2021).

- 67. COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-
- 19. *Nature* **600**, 472–477 (2021).